EW · Edwards Lifesciences Corp
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-11 | Lippis Daniel J. |
CVP, TAVR |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. |
Common Stock
|
619 |
| 2026-08-11 | Lippis Daniel J. |
CVP, TAVR |
Convert↓
|
Employee Stock Option (Right to Acquire)
|
619 |
| 2026-08-11 | Lippis Daniel J. |
CVP, TAVR |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. |
Common Stock
|
619 |
| 2026-07-30 | Markowitz Wayne |
CVP, JAPAC |
Sell↓
|
Common Stock
|
146 |
| 2026-07-28 | Markowitz Wayne |
CVP, JAPAC |
Sell↓
|
Common Stock
|
9,628 |
| 2026-07-28 | Markowitz Wayne |
CVP, JAPAC |
Convert↓
|
Employee Stock Option (Right to Acquire)
|
9,628 |
| 2026-07-28 | Markowitz Wayne |
CVP, JAPAC |
Convert↑
|
Common Stock
|
9,628 |
| 2026-07-27 | Zovighian Bernard J |
Director, CEO |
Sell↓
|
Common Stock
(I)
|
2,920 |
| 2026-07-27 | Zovighian Bernard J |
Director, CEO |
Gift↑
|
Common Stock
(I)
|
319 |
| 2026-07-27 | Zovighian Bernard J |
Director, CEO |
Gift↓
|
Common Stock
|
319 |
| 2026-07-11 | Bruls Annette |
CVP, EMEACLA |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e). |
Common Stock
|
109 |
| 2026-07-10 | Lippis Daniel J. |
CVP, TAVR |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. |
Common Stock
|
619 |
| 2026-07-10 | Lippis Daniel J. |
CVP, TAVR |
Convert↓
|
Employee Stock Option (Right to Acquire)
|
619 |
| 2026-07-10 | Lippis Daniel J. |
CVP, TAVR |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. |
Common Stock
|
619 |
| 2026-07-09 | Mistras Theodora |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
These restricted stock units were granted on July 9, 2026, under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest as follows: 43.75% on the first anniversary of May 29, 2026 (the "Start Date"), 50% on the second anniversary of the Start Date, and the remaining 6.25% on the third anniversary of the Start Date. |
Common Stock
|
87,595 |
| 2026-07-09 | Mistras Theodora |
Chief Financial Officer |
Award↑
Filing footnotes — Performance Rights (Direct)
Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on July 9, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. |
Performance Rights
|
12,325 |
| 2026-07-09 | Mistras Theodora |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
These restricted stock units were granted on July 9, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |
Common Stock
|
12,325 |
| 2026-07-09 | Mistras Theodora |
Chief Financial Officer |
Award↑
Filing footnotes — Employee Stock Option (Right to Acquire) (Direct)
These options were granted on July 9, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |
Employee Stock Option (Right to Acquire)
|
61,800 |
| 2026-07-07 | Lippis Daniel J. |
CVP, TAVR |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e). |
Common Stock
|
377 |
| 2026-06-30 | Lippis Daniel J. |
CVP, TAVR |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. |
Common Stock
|
619 |
| 2026-06-30 | Lippis Daniel J. |
CVP, TAVR |
Convert↓
|
Employee Stock Option (Right to Acquire)
|
619 |
| 2026-06-30 | Lippis Daniel J. |
CVP, TAVR |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. This transaction was executed in multiple trades at prices ranging from $91.185 to $91.650. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
619 |
| 2026-06-17 | Zovighian Bernard J |
Director, CEO |
Sell↓
Filing footnotes — Common Stock (Indirect)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. |
Common Stock
(I)
|
523 |
| 2026-05-29 | Dahl Andrew M. |
SVP, Corporate Controller |
Sell↓
|
Common Stock
|
567 |
| 2026-05-29 | Mistras Theodora |
Chief Financial Officer |
Other↑
|
No Securities Owned
|
0 |
| 2026-05-27 | BOBO DONALD E JR |
CVP,Strategy/Corp Development |
Sell↓
Filing footnotes — Common Stock (Indirect)
This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
(I)
|
23,145 |
| 2026-05-22 | Chopra Daveen |
CVP, TMTT & Surgical |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed in multiple trades at prices ranging from $84.6002 to $84.6050. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
1,500 |
| 2026-05-18 | Lippis Daniel J. |
CVP, TAVR |
Convert↓
|
Employee Stock Option (Right to Acquire)
|
620 |
| 2026-05-18 | Lippis Daniel J. |
CVP, TAVR |
Convert↑
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. |
Common Stock
|
620 |
| 2026-05-18 | Lippis Daniel J. |
CVP, TAVR |
Sell↓
Filing footnotes — Common Stock (Direct)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026. |
Common Stock
|
620 |
| 2026-05-15 | BOBO DONALD E JR |
CVP,Strategy/Corp Development |
Sell↓
|
Common Stock
(I)
|
8,000 |
| 2026-05-15 | BOBO DONALD E JR |
CVP,Strategy/Corp Development |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was executed in multiple trades at prices ranging from $81.975 to $82.260. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
9,968 |
| 2026-05-12 | Zovighian Bernard J |
Director, CEO |
Gift↑
|
Common Stock
(I)
|
26,640 |
| 2026-05-12 | Zovighian Bernard J |
Director, CEO |
Sell↓
Filing footnotes — Common Stock (Indirect)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. This transaction was executed in multiple trades at prices ranging from $77.375 to $78.360. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
(I)
|
35,506 |
| 2026-05-12 | Zovighian Bernard J |
Director, CEO |
Sell↓
Filing footnotes — Common Stock (Indirect)
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. This transaction was executed in multiple trades at prices ranging from $78.390 to $78.430. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
(I)
|
845 |
| 2026-05-12 | Zovighian Bernard J |
Director, CEO |
Gift↓
|
Common Stock
|
26,640 |
| 2026-05-11 | Zovighian Bernard J |
Director, CEO |
Convert↓
Filing footnotes — Performance Rights (Direct)
On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. These Performance Rights expire on May 10, 2030. |
Performance Rights
|
47,207 |
| 2026-05-11 | Ullem Scott B. |
CVP, Chief Financial Officer |
Tax↓
|
Common Stock
|
11,004 |
| 2026-05-11 | BOBO DONALD E JR |
CVP,Strategy/Corp Development |
Convert↓
Filing footnotes — Performance Rights (Direct)
On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. These Performance Rights expire on May 10, 2030. |
Performance Rights
|
13,457 |
| 2026-05-11 | Chopra Daveen |
CVP, TMTT & Surgical |
Tax↓
|
Common Stock
|
7,538 |
| 2026-05-11 | Lippis Daniel J. |
CVP, TAVR |
Tax↓
|
Common Stock
|
362 |
| 2026-05-11 | BOBO DONALD E JR |
CVP,Strategy/Corp Development |
Tax↓
|
Common Stock
|
7,469 |
| 2026-05-11 | Chopra Daveen |
CVP, TMTT & Surgical |
Convert↓
Filing footnotes — Performance Rights (Direct)
On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. These Performance Rights expire on May 10, 2030. |
Performance Rights
|
13,583 |
| 2026-05-11 | Zovighian Bernard J |
Director, CEO |
Gift↓
|
Common Stock
|
5,489 |
| 2026-05-11 | Zovighian Bernard J |
Director, CEO |
Gift↑
|
Common Stock
(I)
|
5,489 |
| 2026-05-11 | Ullem Scott B. |
CVP, Chief Financial Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. |
Common Stock
|
19,830 |
| 2026-05-11 | Chopra Daveen |
CVP, TMTT & Surgical |
Convert↑
Filing footnotes — Common Stock (Direct)
On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. |
Common Stock
|
13,583 |
| 2026-05-11 | Zovighian Bernard J |
Director, CEO |
Convert↑
Filing footnotes — Common Stock (Direct)
On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. |
Common Stock
|
47,207 |
| 2026-05-11 | BOBO DONALD E JR |
CVP,Strategy/Corp Development |
Convert↑
Filing footnotes — Common Stock (Direct)
On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. |
Common Stock
|
13,457 |
| 2026-05-11 | Ullem Scott B. |
CVP, Chief Financial Officer |
Convert↓
Filing footnotes — Performance Rights (Direct)
On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. These Performance Rights expire on May 10, 2030. |
Performance Rights
|
19,830 |